tab‐cel® (tabelecleucel) |
|
Phase
|
Trial Number
|
Trial Description
|
| 3 |
NCT03392142
|
Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With EBV+ PTLD After Failure of Rituximab (MATCH) |
| 3 |
NCT03394365
|
Tabelecleucel for Solid Organ Transplant Subjects With EBV+ PTLD After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE) |
| 1/2 |
NCT03769467
|
Tabelecleucel in Combination With Pembrolizumab in Subjects With EBV+ Nasopharyngeal Carcinoma |
| 1/2 |
NCT00002663
|
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies |
ATA188 |
|
Phase
|
Trial Number
|
Trial Description
|
| 1 |
NCT03283826
|
Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis |
Requests for Expanded Access
This Policy for Requests for Expanded Access to Investigational Drugs describes the principles and procedures that Atara Biotherapeutics will follow when considering requests by licensed physicians for use of Atara’s investigational drugs outside of clinical trials.
Enrollment
For more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.
The safety and efficacy of the investigational use of these products have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.